HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lumican and versican are associated with good outcome in stage II and III colon cancer.

AbstractBACKGROUND:
Tumor stroma plays an important role in the progression and metastasis of colon cancer. The glycoproteins versican and lumican are overexpressed in colon carcinomas and are associated with the formation of tumor stroma. The aim of the present study was to investigate the potential prognostic value of versican and lumican expression in the epithelial and stromal compartment of Union for International Cancer Control (UICC) stage II and III colon cancer.
METHODS:
Clinicopathological data and tissue samples were collected from stage II (n = 226) and stage III (n = 160) colon cancer patients. Tissue microarrays were constructed with cores taken from both the center and the periphery of the tumor. These were immunohistochemically stained for lumican and versican. Expression levels were scored on digitized slides. Statistical evaluation was performed.
RESULTS:
Versican expression by epithelial cells in the periphery of the tumor, i.e., near the invasive front, was correlated to a longer disease-free survival for the whole cohort (P = 0.01), stage III patients only (P = 0.01), stage III patients with microsatellite-instable tumors (P = 0.04), and stage III patients with microsatellite-stable tumors who did not receive adjuvant chemotherapy (P = 0.006). Lumican expression in epithelial cells overall in the tumor was correlated to a longer disease-specific survival in stage II patients (P = 0.05) and to a longer disease-free survival and disease-specific survival in microsatellite-stable stage II patients (P = 0.02 and P = 0.004).
CONCLUSIONS:
Protein expression of versican and lumican predicted good clinical outcome for stage III and II colon cancer patients, respectively.
AuthorsMeike de Wit, Eric J Th Belt, Pien M Delis-van Diemen, Beatriz Carvalho, Veerle M H Coupé, Hein B A C Stockmann, Herman Bril, Jeroen A M Beliën, Remond J A Fijneman, Gerrit A Meijer
JournalAnnals of surgical oncology (Ann Surg Oncol) Vol. 20 Suppl 3 Pg. S348-59 (Dec 2013) ISSN: 1534-4681 [Electronic] United States
PMID22711178 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Chondroitin Sulfate Proteoglycans
  • lumican
  • Versicans
  • Keratan Sulfate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (metabolism)
  • Chondroitin Sulfate Proteoglycans (metabolism)
  • Colonic Neoplasms (metabolism, mortality, pathology)
  • Epithelial Cells (metabolism)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Keratan Sulfate (metabolism)
  • Male
  • Microsatellite Repeats
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local (metabolism, mortality, pathology)
  • Neoplasm Staging
  • Prognosis
  • Stromal Cells (metabolism)
  • Survival Rate
  • Tissue Array Analysis
  • Versicans (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: